J
Jens Grueger
Researcher at Hoffmann-La Roche
Publications - 5
Citations - 444
Jens Grueger is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 3 publications receiving 357 citations.
Papers
More filters
Journal ArticleDOI
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Louis P. Garrison,Adrian Towse,Andrew Briggs,Gérard de Pouvourville,Jens Grueger,Penny Mohr,Johan L. Severens,Paolo Siviero,Miguel Sleeper +8 more
TL;DR: In this article, the authors provide practical recommendations for the development and application of state-of-the-art methods to be used when considering, using, or reviewing performance-based risk-sharing arrangements (PBRSAs).
Споразумения за споделяне на риска, основани на представянето - добра практи- ка на дизайна, приложението и оценката: Доклад на работната група на ISPOR Performance-Based Risk-Sharing Arrangements - Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance- Based Risk-Sharing Arrangements Task Force
Louis P. Garrison,Adrian Towse,Andrew Briggs,Jens Grueger,Penny Mohr,Miguel Sleeper,Cergy Pontoise,F. Hoffmann-La,Agenzia Italiana del Farmaco +8 more
TL;DR: The objective of this Task Force report was to set out the standards that should be applied to "good practices"-both research and operational-in the use of a PBRSA, encompassing questions around the desirability, design, implementation, and evaluation of such an arrangement.
Journal ArticleDOI
Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions
Rick A. Vreman,Inkatuuli Heikkinen,Ad Schuurman,Claudine Sapède,Jordi Llinares Garcia,Niklas Hedberg,Dimitrios Athanasiou,Jens Grueger,Hubert G. M. Leufkens,Wim G. Goettsch +9 more
TL;DR: Insight into the current definitions in use of unmet medical need is provided and stakeholders that want to promote alignment on the concept of UMN are encouraged to prospectively discuss the scope in which they want to apply the concept, what elements they find important for consideration in each case, and how they would measure UMN within the broader regulatory or value framework applicable.
Journal ArticleDOI
HTA104 Opportunities to Improve the Adoption of Quality of Life Data as Part of the French Health Technology Assessment Process
L. Khalfallah Neelz,H. Larose,M M Y Lee,Jens Grueger,Amélie Anota,M. D. Di Palma,Bruno Falissard,S. Palazuelos-Munoz,A Tetafort +8 more
TL;DR: In this article , the authors identify obstacles and potential opportunities by comparing three health systems in France and identify the potential opportunities and potential obstacles of these obstacles by comparing them with three different health systems.
Journal ArticleDOI
The evolving value assessment of cancer therapies: Principles from the cancer community.
Myrto Lee,Anne-Marie Baird,Russell C. Clark,Javier Cortes,Giuseppe Curigliano,Andrea S. Ferris,Ataru Igarashi,Ravindran Kanesvaran,H. Larose,Gary H. Lyman,Luca Pani,Zack Pemberton-Whiteley,Tomas Salmonson,Barry D Stein,Dong-Churl Suh,Galina Velikova,Richard Vines,Jens Grueger +17 more
TL;DR: In this paper , a group of 24 cancer community experts (9 oncologists, 6 patient advocacy leaders, 1 former regulator, 6 former payers, and 4 health economists) from 14 countries came together to discuss and build consensus on oncology-relevant value principles.